A Phase I Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted T Cells Injection for Subjects With BCMA-positive Relapsed/Refractory Multiple Myeloma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Anti CD19 anti BCMA bispecific chimeric antigen receptor T cell therapy Hrain Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Hrain Biotechnology
Most Recent Events
- 25 Feb 2021 Status changed from not yet recruiting to recruiting.
- 02 Jul 2019 New trial record